OncoImmune

News

Merck & Co is to buy US biotech OncoImmune for at least $425m, adding a potential new therapy for COVID-19 to its pipeline.

News

Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.